Shanghai Fosun Pharmaceutical Group Co Ltd
SSE:600196

Watchlist Manager
Shanghai Fosun Pharmaceutical Group Co Ltd Logo
Shanghai Fosun Pharmaceutical Group Co Ltd
SSE:600196
Watchlist
Price: 26.24 CNY -3.78% Market Closed
Market Cap: 67.1B CNY
Have any thoughts about
Shanghai Fosun Pharmaceutical Group Co Ltd?
Write Note

Gross Margin
Shanghai Fosun Pharmaceutical Group Co Ltd

46.5%
Current
48%
Average
48.3%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
46.5%
=
Gross Profit
18.8B
/
Revenue
40.5B

Gross Margin Across Competitors

Country CN
Market Cap 70.1B CNY
Gross Margin
46%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 710.5B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 3.3T DKK
Gross Margin
85%
Country US
Market Cap 373.5B USD
Gross Margin
69%
Country US
Market Cap 251.1B USD
Gross Margin
77%
Country CH
Market Cap 202.7B CHF
Gross Margin
73%
Country CH
Market Cap 183.3B CHF
Gross Margin
75%
Country UK
Market Cap 162.4B GBP
Gross Margin
82%
Country IE
Market Cap 146B USD
Gross Margin
68%
No Stocks Found

Shanghai Fosun Pharmaceutical Group Co Ltd
Glance View

Market Cap
70.1B CNY
Industry
Pharmaceuticals

Shanghai Fosun Pharmaceutical Group Co., Ltd. is a leading player in the global healthcare landscape, anchored in its commitment to innovation and quality. Founded in 1994 and based in Shanghai, China, the company operates through a diverse portfolio that includes pharmaceuticals, biotechnology, medical devices, and healthcare services. With a strategic focus on research and development, Fosun Pharma has developed a strong pipeline of proprietary drugs and vaccines, enhancing its position in both domestic and international markets. Its ability to capitalize on China’s booming healthcare sector, alongside strategic alliances with reputable global firms, positions it as a formidable competitor in the ever-evolving landscape of healthcare. For investors, Fosun Pharma presents an intriguing opportunity, characterized by robust growth potential and strategic expansion initiatives. Over recent years, the company has aggressively pursued both organic growth and acquisitions to strengthen its product offerings and market reach. This includes partnerships with renowned companies to develop cutting-edge treatments and technologies. The organization’s emphasis on global healthcare trends, along with its commitment to enhancing patient well-being through innovative solutions, underscores its long-term vision. Investors can view Fosun Pharma as a vital player in addressing healthcare needs, especially in the wake of increasing global demand for health solutions, thus making it an attractive proposition in the pharmaceutical industry.

Intrinsic Value
38.86 CNY
Undervaluation 32%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
46.5%
=
Gross Profit
18.8B
/
Revenue
40.5B
What is the Gross Margin of Shanghai Fosun Pharmaceutical Group Co Ltd?

Based on Shanghai Fosun Pharmaceutical Group Co Ltd's most recent financial statements, the company has Gross Margin of 46.5%.